Fosfomycin Co-Administration for Resistant Bacterial Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibiotic treatments for Gram-negative and Gram-positive bacterial infections, particularly those resistant to multiple drugs, face challenges in achieving optimal dosing strategies that minimize drug resistance and maximize efficacy, as existing dosing regimens may not effectively target resistant subpopulations of bacteria like Klebsiella pneumoniae, Pseudomonas aeruginosa, and Staphylococcus aureus.
Innovation Solution
The use of a co-administration regimen involving fosfomycin, either alone or in combination with antimicrobial agents such as piperacillin-tazobactam, ceftazidime, and meropenem, to effectively reduce bacterial density and inhibit resistant mutant subpopulations, with the option of varying fosfomycin doses relative to the antimicrobial agents to achieve synergistic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing dosing regimens are used for multi-drug resistant bacteria, then treatment simplicity is maintained, but efficacy against resistant subpopulations is insufficient
Solution Approach 1:
The patent combines multiple antimicrobial agents with different mechanisms of action into a single dosing regimen. Specifically, it integrates fosfomycin (which inhibits an early step in peptidoglycan biosynthesis) with other antibiotics that target different bacterial pathways, creating a synergistic effect that eliminates resistant subpopulations while maintaining dosing simplicity through co-administration.
Solution Approach 2:
The invention creates a composite dosing strategy that layers multiple antimicrobial mechanisms together. By combining agents with divergent modes of action (e.g., cell wall synthesis inhibition by fosfomycin with other antibiotic classes), the regimen achieves enhanced efficacy against heterogeneous bacterial populations including resistant mutants, while the composite approach allows for optimized dosing schedules that balance effectiveness with administrative simplicity.
2Reliability
If fosfomycin is combined with multiple antimicrobial agents, then synergistic bacterial killing is enhanced, but the dosing regimen complexity increases
Solution Approach 1:
The patent optimizes dosing parameters by adjusting the timing, dosage, and administration sequence of fosfomycin in combination with other antimicrobial agents. Through population pharmacokinetic modeling and PK/PD target attainment analysis, the regimen identifies specific dosing intervals and concentration targets that maximize synergistic bacterial killing while minimizing regimen complexity. This includes determining optimal fosfomycin dosing relative to other agents based on their pharmacokinetic profiles and mechanisms of action.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach demonstrates enhanced bacterial killing and synergy against multi-drug resistant bacteria, including Klebsiella pneumoniae, Pseudomonas aeruginosa, and Staphylococcus aureus, reducing the potential for on-therapy drug resistance and improving treatment outcomes by maintaining broad-spectrum activity against resistant pathogens.
Implementation Method 1
FOS inhibits an early step in cell wall synthesis via covalent binding to MurA
Data Source
AI summary
Methods of treating a Gram negative bacterial infection comprising a co-administration regimen of an effective amount of fosfomycin together with at least one antimicrobial agent selected from the group consisting of piperacillin-tazobactam, ceftazidime and meropenem to an infected subject. A further method of treating a subject with a bacterial infection that includes infection with a “resistant” mutant subpopulation selected from the group consisting of Staphylococcus aureus, Enterococcus faecalis, Pseudomonas aeruginosa, Acinetobacter baumannii and E. coli, the method comprising (a) obtaining a sample from a subject suffering from a bacterial infection; (b) identifying the presence of the “resistant” mutant subpopulation in said sample; and (c) co-administering fosfomycin and at least one antimicrobial agent to the subject, wherein after the co-administration, the bacterial density is effectively reduced and the “resistant” mutant subpopulation is inhibited.